Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008